The Random Forests machine learning method is a useful tool to help ophthalmologists distinguish between the visual fields (VFs) of individuals with healthy eyes and those with preperimetric open-angle glaucoma (OAG) in which glaucoma will manifest, according to research from Japan.
Anterior capsulotomies may be created safely and efficaciously using a femtosecond laser system (Catalys Precision Laser System, Abbott Medical Optics), according to a study published online in the Journal of Cataract & Refractive Surgery.
Extensive pars plana vitrectomy and cataract extraction can significantly improve visual acuity in juvenile idiopathic arthritis patients suffering from severe ocular complications of uveitis.
When compared with eyes of normal axial length, high-myopic pseudophakic eyes with posterior staphyloma had significantly less internal coma and less coma variations during mydriasis, according to recently published research.
Two trifocal IOLs enabled patients to have "a useful third focus for intermediate vision", but also resulted in increased background halos and reduced distance visual quality compared with a multifocal IOL, according to new research.
iSTAR Medical SA announced that the first patient in its European multicentre clinical trial has been successfully implanted with the company's STARflo glaucoma drainage device.
Patients with myopia of greater than -6.00 dioptres (D) who underwent femtosecond laser-assisted LASIK, experienced a more significant decrease in corneal hysteresis, corneal resistance factor, and p1 and p2 areas than patients who underwent small incision lenticule extraction (SMILE).
Ophthalmologists may use nonmydriatic retinal imaging to supplement the standard clinical exam to screen diabetic children aged as young as 2 years, according to newly published research.
Patients with diabetic macular oedema (DME) who received aflibercept injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.
A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.
The findings of a new study will enable clinicians to make more accurate diagnoses of multiple sclerosis (MS) and uveitis while giving people a better understanding of their prognoses, according to its authors.
UK sight loss charities RP Fighting Blindness and Fight for Sight are joining forces to drive a project that will accelerate understanding of the genetic causes of inherited retinal dystrophies (IRD).
Patients with moderate and severe meibomian gland dysfunction (MGD) may benefit from topical loteprednol etabonate and eyelid scrubs with warm compresses, according to researchers in South Korea.
Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).
Monovision correction and multifocal IOLs work well for correcting distance vision, with multifocal IOLs reducing the need for glasses but significantly increasing dysphotopsia for those who underwent implantation.
There is a correlation between functional cell loss in the retina and signs of dementia in people who have a genetic risk for frontotemporal dementia (FTD), according to researchers from the US.
Researchers at the University of Reading, UK, report that they have discovered a potential way of making eye drops more effective.
The US Food and Drug Administration (FDA) has approved a low-dose corticosteroid intravitreal implant for the treatment of diabetic macular oedema. (DME).
The Royal College of General Practitioners and the UK Vision Strategy initiative have produced a new guide, Sight Loss in Older People: The Essential Guide for General Practice.
Daily supplementation with selenium and/or vitamin E is unlikely to have a large preventive effect on the development of age-related cataracts, according to data from a recent study.
Monthly monitoring is no longer required for patients taking ranibizumab (Lucentis, Novartis) for a condition that is stable, due to a change in the drug's licence.
Cataract surgery is associated with a reduced risk of dementia later in life, researchers in Taiwan have found.
Anti-glaucoma preparations that do not contain benzalkonium chloride (BAK) were associated with a change in lubricant use in a study of 240 glaucoma patients, suggesting reduction in some ocular surface disease symptoms, according to research published online.
The European Society of Ophthalmology (SOE) and the American Academy of Ophthalmology (AAO) are holding a joint meeting 17 to 21 October at McCormick Place in Chicago, Illinois, USA. The meeting will be AAO's 118th annual meeting.
Non-damaging photothermal therapy using a pattern-scanning laser (PASCAL) guided by proprietary software is a safe and effective treatment for chronic central serous retinopathy (CSR), according to a recent study.
It's important to evaluate tear osmolarity during surgical planning to ensure that pre-surgical keratometry readings are not compromised by hyperosmolarity of the ocular surface.
Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications
Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself.
CataRhex 3 ? Phaco without Limits Never before has cutting-edge technology for anterior segment surgery been as easily and reliably available, and never before has its packaging been more compact and tempting.
The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.